

EXECUTIVE BOARD 154th session Agenda item 13

Financial and administrative implications for the Secretariat of decisions proposed for adoption by the Executive Board

Decision: Antimicrobial resistance: accelerating national and global responses

A. Link to the approved Programme budget 2024–2025

1. Output(s) in the approved Programme budget 2024–2025 under which this draft decision would be implemented if adopted:

1.3.5. Countries enabled to address antimicrobial resistance through strengthened surveillance systems, laboratory capacity, infection prevention and control, awareness-raising and evidence-based policies and practices

2. Short justification for considering the draft decision, if there is no link to the results as indicated in the approved Programme budget 2024–2025:

Not applicable.

3. Any additional Secretariat work during the biennium 2024–2025 that cannot be accommodated within the approved Programme budget 2024–2025 ceiling:

Not applicable.

 $\textbf{4.} \hspace{0.5cm} \textbf{Estimated time frame (in years or months) to implement the decision:} \\$

11 years (2025–2035).

- B. Resource implications for the Secretariat for implementation of the decision
- 1. Total budgeted resource levels required to implement the decision, in US\$ millions: US\$ 503.25 million.
- 2.a. Estimated resource levels required that can be accommodated within the approved Programme budget 2024–2025 ceiling, in US\$ millions:

US\$ 41.03 million.

Only anticipated costs for 2025 have been included to align with the estimated time frame.

2.b. Estimated resource levels required in addition to those already budgeted for in the approved Programme budget 2024–2025, in US\$ millions:

Not applicable.

3. Estimated resource levels required to be budgeted for in the proposed programme budget for 2026–2027, in US\$ millions:

US\$ 85.34 million.

4. Estimated resource levels required to be budgeted for in the proposed programme budgets of future bienniums, in US\$ millions:

US\$ 376.88 million.

- 5. Level of resources already available to fund the implementation of the decision in the current biennium, in US\$ millions
 - Resources available to fund the decision in the current biennium:

US\$ 10.22 million.

- Remaining financing gap in the current biennium:

US\$ 30.81 million.

- Estimated resources, which are currently being mobilized, if any, that would help to close the financing gap in the current biennium:

US\$ 23.00 million.

Partners supporting WHO's work on antimicrobial resistance: Asia-Europe Foundation, Centers for Disease Control and Prevention (United States of America), Denmark, European Commission, Fleming Fund (United Kingdom of Great Britain and Northern Ireland), Foundation for Innovative New Diagnostics, France, Global Antibiotic Research and Development Partnership, Germany, Japan, Netherlands (Kingdom of the), Norwegian Agency for Development Cooperation, Republic of Korea and Saudi Arabia.

Table. Breakdown of estimated resource requirements (in US\$ millions)^a

Biennium	Costs	Region						Headquarters	Total
		Africa	The Americas	South-East Asia	Europe	Eastern Mediterranean	Western Pacific		
B.2.a. 2024–2025 resources already planned	Staff	2.31	1.20	1.95	1.85	1.22	1.00	11.90	21.41
	Activities	1.95	1.43	1.95	2.36	1.74	1.13	9.06	19.61
	Total	4.26	2.63	3.89	4.21	2.96	2.13	20.95	41.03
B.2.b. 2024–2025 additional resources	Staff	_	_	_	-	_	-	-	_
	Activities	_	_	_	-	_	_	_	_
	Total	_	_	_	-	_	-	-	_
B.3. 2026–2027 resources to be planned	Staff	4.80	2.49	4.05	3.84	2.54	2.07	24.74	44.54
	Activities	4.06	2.98	4.05	4.91	3.61	2.35	18.84	40.80
	Total	8.86	5.47	8.10	8.75	6.15	4.42	43.58	85.34
B.4. Future bienniums resources to be planned	Staff	21.20	11.01	17.87	16.96	11.22	9.16	109.27	196.70
	Activities	17.94	13.14	17.89	21.68	15.95	10.36	83.21	180.18
	Total	39.14	24.15	35.77	38.64	27.17	19.52	192.48	376.88

^a The row and column totals may not always add up, owing to rounding.

= = =